Arvinas and Pfizer to Co-develop and Commercialize Breast Cancer Therapy
Arvinas and Pfizer have announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera)
Read moreArvinas and Pfizer have announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera)
Read moreThe CTAT Enzymatic Antibody Drug Conjugation Technology -Benefits for Diagnostic Applications and ADC’s for Oncology. A EUCODIS Bioscience Case Study
Read moreQIAGEN officially confirmed a global cooperation agreement with Sysmex Corporation for the development and commercialization of cancer companion diagnostics, leveraging
Read moreNucleai and Merck KGaA will collaborate utilizing Nucleai’s AI-powered platform to develop pathology-based biomarkers as companion diagnostics. Nucleai, a precision
Read moreAleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a partnership to advance the early phase clinical development of Aleta’s
Read moreKite, a Gilead Company, and Shoreline Biosciences have announced a $2.3 Billion strategic partnership to develop novel cell therapies across
Read moreEngine Biosciences, a company deciphering complex biology to unleash impactful therapeutics plans to use funds from a $43 million funding
Read moreThe European Commission has approved Astellas’ XTANDI™ (enzalutamide) for men with metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Japanese multinational pharmaceutical company
Read moreEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) revealed that it has invested in OxVax, a new immuno-oncology organization
Read moreBristol-Myers Squibb is investing in a brand new cell therapy facility which will be located at the Leiden Bio Science
Read more